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Abstract
Background: Diabetic retinopathy (DR) is a common microvascular complication of diabetes mellitus, and more than 75% of
patients who have had diabetes for more than 20 years will have some degree of DR. This disease is highly destructive to self-esteem
and puts a high burden on public health and pension systems due to the effects that it has on people of working age. The current
mainstay of treatment is laser photocoagulation, which causes impairment of vision and discomfort to patients. Thus, finding a
systemic drug that could act on all microcirculation and prevent direct manipulation of the eyes would be highly desirable.
Objective: To assess the efficacy and safety of the drugs in the statin and/or fibrate groups for the prevention and treatment of
DR.
Methods: In this systematic review, we will select randomized controlled trials of fibrates or statins used for the treatment or
prevention of DR. Our search strategy will include free text terms and controlled vocabulary (eg, MeSH, Emtree) for, “diabetic
retinopathy”, “statins”, “fibrates”, “hypolipidemic agents”, and for drugs from both groups. Databases that will be used include
Medical Literature Analysis and Retrieval System/PubMed, Embase, Cochrane Central Register of Controlled Trials, Latin
American and Caribbean Center on Health Sciences Information, Clinicaltrials.gov, World Health Organization International
Clinical Trials Registry Platform, and OpenGrey, and we will not have language or date limits. Two review authors will
independently select eligible studies and assess the risk of bias using the Cochrane Collaboration’s tool. We will report structured
summaries of the included studies and, if possible, conduct meta-analyses.
Results: This is a protocol for a systematic review, therefore results are not available. We registered a short version of this
protocol before progressing in the review and we are currently in the process of selecting the studies for inclusion.
Conclusions: Intensive glucose control and lowering blood pressure and lipids are mechanisms that protect macrocirculation
in diabetic patients. Both macrovascular and microvascular events in diabetic patients appear to have a common pathway, starting
with endothelial injury. Thus, prevention and treatment of microvascular events may benefit from the same interventions. In the
review for which we have written this protocol, we will assess whether the use of lipid-lowering oral drugs of the statin and/or
fibrate groups may prevent and/or retard progression of DR, with the added benefit of preserving visual acuity.
Trial Registration: PROSPERO CRD42016029746
(JMIR Res Protoc 2017;6(2):e30)   doi:10.2196/resprot.6650
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Introduction
Diabetic retinopathy (DR) is a common microvascular
complication of diabetes mellitus, and more than 75% of patients
who have had diabetes for more than 20 years will have some
degree of DR [1]. This disease is the leading cause of blindness
among working-age Americans [2]. It is estimated that 33,000
new cases of diabetic macular edema, 86,000 new cases of
proliferative DR, and 12,000-14,000 new cases of blindness are
caused by DR each year in the United States alone [1].
Projections compute that by 2050 the number of Americans
aged 40 years and older with DR and vision-threatening DR
will triple compared to 2005 numbers (from 5.5 million to 16.0
million for the former and 1.2 million to 3.4 million for the
latter) [3].
A putative pathophysiological mechanism of the disease is
through products of nonenzymatic glycosylation, named
advanced glycosylation end products (AGEs) [4,5]. AGEs are
proteins or fats that become glycated after exposure to sugar,
and the oxidative stress that occurs in diabetes is one of the
probable causes that triggers this reaction [6]. AGEs bind to
receptors in the retinal vessel endothelium and trigger the
extrinsic pathway of coagulation, along with the inhibition of
protein C (a physiological anticoagulant), and increase
production of endothelin-1 (a potent vasoconstrictor) [7].
Together, these cascades lead to narrower vessels, increased
permeability of the vascular wall, and consequently tissue
ischemia. Ischemia, in turn, attracts angiogenic factors that
promote neovascularization [8]. Lipids also presumably play
an important role in the exudative stage of DR. The increased
permeability of retinal capillaries causes extravasation of plasma
lipoproteins that (along with degenerating cells) are engulfed
by macrophages and form hard exudates, which is a defining
characteristic of this stage of the disease [9].
Numerous studies on the newer antivascular endothelial growth
factor drugs for the treatment of DR have been conducted, but
laser photocoagulation persists as the treatment with the highest
level of efficacy and safety [10]. However, even being the first
option of treatment, laser photocoagulation is frequently
associated with irreversible side effects caused by the ablation
of retinal tissue. Visual field loss and impairment of night vision
are frequent, and the procedure itself is very painful [11]. In
this capacity, systemic drugs are highly desirable since they
might prevent the onset and progression of DR, thereby avoiding
the harms of manipulating the eye. Drugs might also allow for
the chance to act in a preventive manner across the entire
vascular endothelium.
It is known that all vascular diabetic alterations, whether in
macrocirculation or microcirculation, have a common
endothelial start. It is also well known that inadequate glycemic
control, hypertension, and dyslipidemia are risk factors for the
development of macrovascular disease in diabetics. Although
the importance of the first two factors in microcirculation have
already been addressed by previous systematic reviews [12,13],
the relationship between lipids and the development and severity
of DR is complex and remains unclear [14].
A recent update of The Wisconsin Epidemiologic Study of
Diabetic Retinopathy, a 30-year follow-up of approximately
903 patients, found no association between total cholesterol or
high density lipoprotein (HDL) and incidence of DR or macular
edema, while there was a modest association between higher
levels of HDL and decreased prevalence of proliferative DR
[15]. The investigators then concluded that total cholesterol and
HDL (as well as statin use) had a modest impact on DR [15].
Studies examining dietary lipid interventions showed favorable
variable results in DR progression [16-18]. Other studies with
clofibrate found reductions in hard exudates, but did not find
differences in visual acuity [19-21].
Conversely, some randomized controlled trials (RCTs) showed
beneficial effects of hypolipidemic drugs, suggesting that they
may slow the progression of DR. The Action to Control
Cardiovascular Risk in Diabetes (ACCORD) Eye Study, for
example, evaluated the effects of specific strategies for managing
blood glucose levels, serum lipid levels, and blood pressure on
cardiovascular events in participants with type 2 diabetes [22].
This study also assessed the effects of these medical strategies
on the progression of DR in a subgroup of trial participants:
results showed that patients with type 2 diabetes who received
fenofibrate and simvastatin had less progression of DR at 4
years when compared to placebo (6.5% vs 10.2% respectively;
P=.006) [22]. Similarly, the Fenofibrate Intervention and Event
Lowering in Diabetes study concluded that monotherapy with
fenofibrate resulted in a significant reduction in the need for
laser therapy at 5 years for either macular edema or proliferative
retinopathy when compared to the placebo group (3.4% vs 4.9%;
P<.001) [23]. Nevertheless, in the study that followed ACCORD
patients (known as the Action to Control Cardiovascular Risk
in Diabetes Follow-On Eye Study), this difference disappeared
8 years after randomization in the original ACCORD study
(11.8% vs 10.2% respectively; P=.60) [22].
In light of these conflicting results, and considering the absence
of the highest level of evidence for this question, it is critical to
summarize the efficacy and safety of statins and fibrates for the
prevention and treatment of DR through a systematic review of
RCTs.
Objectives
To assess the efficacy and safety of the drugs of the statins
and/or fibrates groups for the prevention and treatment of DR.
Methods
This protocol is registered in PROSPERO (CRD42016029746).
We developed the protocol according to the Cochrane Handbook
of Interventions Reviews [24] and report it according to the
Preferred Reporting Items for Systematic Review and
Meta-Analysis (PRISMA) Protocols [25].
Types of Studies
For the purposes of this systematic review, only RCTs will be
included. Given the progressive nature of the clinical situation,
cross-over designs will not be considered.
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Types of Patients
Patients with type 1 or 2 diabetes, with or without
nonproliferative retinopathy (for treatment and prevention,
respectively) will be considered. Patients with proliferative
retinopathy will be excluded.
Types of Interventions
The interventions considered will be any drug from the statin
or fibric acid groups, either in isolation or compared to placebo,
no intervention, or a different type of statin or fibrate. We will
also consider any statin or fibric acid as adjunctive therapy if
we find RCTs of main therapy with statin or fibrate versus main
therapy with placebo, no intervention, or a different type of
statin or fibrate. Photocoagulation may be considered as a main
therapy in this schema. In each situation (isolation or adjunctive)
we will consider studies with any dose or any duration course
of the intervention.
Types of Outcome Measures
Primary Outcomes
Our primary outcomes will include: (1) aiming prevention, the
proportion of patients that develop DR; (2) aiming treatment,
the proportion of patients with progression of DR; and (3)
aiming safety, the proportion of patients with at least one serious
adverse event (ie, those that are immediately life-threatening,
or resulted in hospitalization, incapacity, malignant disease, or
death).
DR will be defined as 35 or more points in the Early Treatment
Diabetic Retinopathy Study (ETDRS) scale [26], based on
evaluation of stereoscopic color fundus photographs of the eyes
of participants who did not have retinopathy at baseline. This
score is equivalent to the categories of mild nonproliferative
DR, or more severe DR [27].
Progression will be defined as a change from baseline of 2 or
more steps on the same scale. We will accept trials that describe
outcomes in terms of steps in the ETDRS scale and trials that
described outcomes that can be converted to the ETDRS scale
(eg, for older trials). For the adverse events outcome, we will
not conduct additional searches in nonrandomized studies, which
are not included in this review.
We plan to assess these outcomes at 2, 6, 12, 18, and 24 months,
and annually thereafter, grouping the trials that fall within these
time points (eg, group trials that assess the outcomes up to 2
months).
Secondary Outcomes
We will assess the proportion of patients with: (1) decrease of
visual acuity (any decrease) measured by Snellen or LogMAR
charts, and (2) proliferative DR (measured by the ETDRS scale)
with at least one minor adverse event (ie, adverse events not
included in the serious adverse event outcome). We will also
evaluate quality of life measured by the National Eye Institute
Visual Functioning Questionnaire 25 or another validated
vision-related scale. These outcomes will be assessed at the
same time points as the primary outcomes.
Methods for Search
Electronic Search
We will systematically search the following databases: Medical
Literature Analysis and Retrieval System (via PubMed), Embase
(via Elsevier), Latin American and Caribbean Center on Health
Sciences Information (via Virtual Health Library), and Cochrane
Central Register of Controlled Trials (via Wiley). The search
strategy will include controlled vocabulary (eg, MeSH, Emtree)
and free-text terms related to, “diabetic retinopathy”,
“hypolipidemic agents”, “statins”, “fibrates”, and drugs from
both groups. No limits for data, language, or status of the
publication (eg, conference abstracts, full-text, ongoing studies)
will be used. Additional searches will be conducted in the
clinical trial registries of Clinicaltrials.gov and the World Health
Organization International Clinical Trials Registry Platform,
and in the grey literature source OpenGrey.
Hand Search
We will assess reference lists of all included studies and review
articles for additional references. We will contact authors of
identified trials and ask them about other published and
unpublished studies. We will also contact manufacturers and
specialists in the field of ophthalmology.
Selection of Studies
Two authors (VM and CGF) will independently read the
references and select the studies according to the inclusion and
exclusion criteria. We will exclude duplicates and collate
multiple reports of the same study so that each study, rather
than each report, will be the unit of interest in the review. After
the initial step of screening titles and abstracts of the records,
we will read the full text articles for the potentially includible
studies, finally deciding on the included ones and giving reasons
for the exclusions in this step. A third reviewer (RR) will resolve
any disagreements. We will record the selection process in
sufficient detail to fulfill a PRISMA flow diagram and a
characteristics of excluded studies table [28].
Data Extraction and Management
We will use a standard data collection form for extracting study
characteristics and outcome data. Two reviewers (VM and CGF)
will extract the study characteristics outlined in Textbox 1.
Textbox 1. Characteristics that will be extracted from the included studies.
• Methods: study design, total duration of study and run-in, number of study centers and location, study setting, withdrawals, and date of study.
• Participants: N, mean age, age range, gender, severity of condition, diagnostic criteria, inclusion criteria, and exclusion criteria.
• Interventions: intervention, comparison, concomitant medications, and excluded medications.
• Outcomes: primary and secondary outcomes (the final outcomes reported and those planned), and time points reported.
• Notes: funding for trial and notable conflicts of interest of trial authors.
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One reviewer (VM) will copy the data from the data collection
form into the Review Manager (RevMan 5.3) file [28]. We will
double check that the data is entered correctly by comparing
the study reports with how the data is presented in the systematic
review.
Assessment of Risk of Bias in Included Studies
Two reviewers (VM and CGF) will independently judge the
risk of bias of each study using the Cochrane Collaboration's
tool for assessing risk of bias [29]. The tool comprises the
following domains: (1) random sequence generation, (2)
allocation concealment, (3) blinding of participants and
personnel, (4) blinding of outcome assessment, (5) incomplete
outcome data, (6) selective outcome reporting, and (7) other
bias. Each domain will be judged as high risk, low risk, or
unclear risk of bias according to the criteria described in the
risk of bias table in the Cochrane Handbook [29]. We will
consider blinding separately for different key outcomes when
necessary (eg, regarding unblinded outcome assessment, risk
of bias for all-cause mortality may be very different than that
of a patient-reported quality of life scale [28]). When considering
treatment effects, we will take into account the risk of bias of
the studies that contributed to that outcome.
Data Synthesis
We will use a software Review Manager (RevMan 5.3) to
perform meta-analyses whenever possible. We plan to use
random-effects meta-analyses except when involving up to 3
studies in the pooled estimate; a situation in which we will use
fixed-effects. This approach is a change from our previous
protocol, in which we would use fixed-effects models for
homogeneous studies and random-effects otherwise; however,
random-effects models result in pooled estimates similar to
fixed-effects models when there is little or no heterogeneity
within studies. Additionally, random-effects analyses provide
poor estimates for the confidence interval when examining few
studies or when the studies are small [30]. If we are not able to
analyze studies due to a lack of data for any comparison, or high
heterogeneity as specified in the assessment of heterogeneity
section, we will report the result of each individual trial
narratively.
Measures of Treatment Effect
We will analyze dichotomous data as risk ratios and continuous
data as mean differences or standardized mean differences. We
will undertake meta-analyses only when meaningful (ie, if the
treatment participants and the underlying clinical question are
similar enough for pooling to make sense). If multiple trial arms
are reported in a single trial, we will include only the relevant
arms, and if two comparisons from the same trial (eg, drug X
vs placebo and drug Y vs placebo) must be included in the same
meta-analysis, we will halve the control group to avoid double
counting [28].
Dealing with Missing Data
We will contact authors or study sponsors to verify key study
characteristics or to obtain missing numerical outcome data
when possible (eg, when a study is identified as abstract only).
If outcome data are missing in both intervention groups, but
reasons for these are both reported and balanced across groups,
important bias would not be expected unless the reasons have
different implications in the compared groups. In dichotomous
studies, the potential impact of missing data depends on the
frequency or risk of outcomes. In continuous outcomes, the
potential impact increases with the proportion of participants
with missing data [29].
Assessment of Heterogeneity
We will assess studies regarding clinical and methodological
heterogeneity. If studies are deemed homogeneous in these
criteria, we will conduct meta-analyses and analyze statistical
heterogeneity by visual inspection of the forest plots, and use
Chi-squared and I2tests. Results of Chi-squared <0.10 and
I2>50% will be considered heterogeneous; in these cases, we
will try to explain heterogeneity by the prespecified groups for
the subgroup analysis and also by the possible findings of the
assessment of publication bias [30].
Assessment of Reporting Bias
If 10 or more studies are included in the meta-analysis, we will
assess reporting biases using funnel plots and visually inspect
the plots for asymmetry [29].
Subgroup Analyses and Investigation of Heterogeneity
Subgroup analyses for the primary outcomes will be conducted
and consider the following groups: the different types of
diabetes, the different kinds of hypolipemic drugs (statins,
fibrates), the different doses of these drugs (eg, high-dose
fibrates), and the dyslipidemia and/or diabetic macular edema
status of the patients [30].
Sensitivity Analyses
Sensitivity analyses will be conducted to determine the impact
of exclusion of studies with overall high risk of bias. Such
studies will include those judged to harbor high risk of bias in
at least one of the main domains in the Risk of Bias Table
(generation of randomization sequence, allocation concealment,
and blinding) [30].
Summary of Findings
Using GRADEpro software we will generate two summary of
findings (SoF) tables, one for each key question of this review:
development and progression of DR. We will use the five
Grading of Recommendations Assessment, Development, and
Evaluation criteria (study limitations, consistency of effect,
imprecision, indirectness, and publication bias) to assess the
quality of the body of evidence that contributes data to the
meta-analyses for the prespecified outcomes. We will use the
methods and recommendations described in Section 8.5 [29]
and Chapter 12 [31] of the Cochrane Handbook for the judgment
of these criteria. We will justify all decisions to downgrade or
upgrade the quality of studies using footnotes, and make
comments to aid readers’ understanding of the review when
necessary. We will consider whether there is any additional
outcome information that was not incorporated into
meta-analyses, note this in the comments, and state if it supports
or contradicts the information from the meta-analyses. The SoF
table regarding the prevention of DR will comprise the following
outcomes: (1) the proportion of patients with DR, (2) the
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proportion of patients with at least one serious adverse event,
(3) the proportion of patients with proliferative DR, and (4) the
proportion of patients with any decrease in visual acuity. The
comparison for this table will be hypolipidemic drugs versus
placebo or no intervention.
The SoF table regarding the treatment of DR will comprise the
following outcomes: (1) the proportion of patients with
progression of DR, (2) the proportion of patients with at least
one serious adverse event, (3) the proportion of patients with
proliferative DR, and (4) the proportion of patients with any
decrease in visual acuity. The comparison for this table will be
laser photocoagulation with hypolipidemic drugs versus laser
photocoagulation with placebo or no intervention. The outcomes
for both SoF tables will be reported at 6 months and 5 years
(short- and long-term, respectively).
Results
This is a protocol for a systematic review, therefore results are
not available. We registered a short version of this protocol
before progressing in the review and we are currently in the
process of selecting the studies for inclusion.
Discussion
Dyslipidemia is one well-known risk factor for the development
of vascular disease in diabetics. However, to date the effects of
statin and/or fibrate use have not been addressed by a systematic
review. The findings of this review will provide an assessment
of the existing evidence for patients and health care providers
that deal with this severe and prevalent complication of diabetes.
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